

19 August 2016

The Manager Companies Announcement Office Australian Securities Exchange Electronic Lodgment

Dear Sir/Madam,

ASX RELEASE – COLLABORATION AGREEMENT BETWEEN THE TUNKU LAKSAMANA JOHOR CANCER FOUNDATION AND AAMG

The Board of Directors (the "Board") of Asian American Medical Group Limited ("AAMG" or "the Company") wishes to announce that it has, on 16 August 2016, entered into a Collaboration Agreement ("CA") with the Tunku Laksamana Johor Cancer Foundation ("TLJCF") (collectively, the "Parties" and each, a "Party").

TLICF was set up, inter alia, for the purpose of assisting and giving relief and care to persons suffering from cancer and their families; the advancement of research, public education in the prevention, control, diagnosis and treatment of cancer; to provide or procure counselling services and guidance in furtherance of the said objectives; and to foster national and international co-ordination and development of all activities in relation to cancer in the State of Johor, Malaysia.

Under the terms of the CA, both Parties have agreed to determine the feasibility of establishing a centre of excellence to provide an array of medical treatment (including but not limited to cancer treatment, organ transplant and other related medical services) in Iskandar Malaysia ("Proposed Project").

The Parties will discuss in good faith, with the intention of arriving at final transaction documents ("Definitive Agreements") in respect of the terms and conditions of the collaboration to implement the Proposed Project. The discussions shall include but not be limited to:-

- (a) exploring and agreeing on the possible formal collaboration structure between TLICF and AAMG which may require the Parties entering into a land lease agreement with TLICF as the lessor and AAMG as the lessee; and
- (b) the business plan and the financial model.

AAMG will use its reasonable endeavours to undertake preliminary feasibility studies, including:

- (a) scoping of services to be provided by the Proposed Project;
- (b) to prepare an outline of a business plan including financial projections;
- (c) to identify the list of medical equipment (including the costs) needed for the Proposed Project;



- (d) to build a financial model which shall include but not be limited to identifying the sources of funds and taking the lead in fund raising to enable the execution and commencement of the operations of the Proposed Project; and
- (e) if the feasibility studies show the Proposed Project is not viable, AAMG shall officially advise TLJCF in writing of its intention whether to proceed with the Proposed Project.

The CA, which is non-binding, will be effective for three (3) months with automatic renewal for another three (3) months or until execution of the Definitive Agreements. Either party may terminate the CA at any time by giving notice in writing.

For more information, please contact:

DARIO NAZZARI

Company Secretary Tel: +61 8 8110 0999

Email: dario@uhyhn.com.au

About Asian American Medical Group

Asian American Medical Group ("AAMG") is based in Singapore and has been listed on the Australian Securities Exchange since September 2009. The Group's operations include the Asian American Liver Centre Pte Ltd ("AALC"), established in 1994 in Singapore, and Asian American Radiation Oncology Pte Ltd ("AARO").

The Group entered into a strategic collaboration in October 2012 with the US-based US\$12-billion integrated global health enterprise UPMC. UPMC, ranked No. 12 on the U.S. News & World Report Honor Roll of American's Best Hospitals, is affiliated with the University of Pittsburgh Schools of the Health Sciences and are pioneers in the field of transplantation. This collaboration has enhanced AAMG's clinical capabilities through shared protocols, rigorous quality standards and technology and also created a platform for AAMG to expand into other countries in Asia such as Malaysia and Myanmar.

AALC, one of Asia's foremost liver centres, is led by renowned hepatobiliary expert and liver transplant surgeon, Dato' Dr. Tan Kai Chah (Dr. KC Tan), who helped start the Liver Transplant Programme at the King's College Hospital London, UK, and pioneered the highly successful Living Donor Liver Transplantation (LDLT) Programme in Singapore. In 2004, AALC begun conducting surgical procedures at IHEAL Medical Centre, located in Kuala Lumpur, Malaysia.

AARO, established in March 2015, offers radiation oncology clinical, consultancy and management services and is spearheaded by Dr Daniel Tan Yat Harn. Based in Singapore, AARO will drive expansion into the growing radiotherapy and oncology segment in the overseas market, at a time where there is a shortage of modern radiotherapy treatment centres.

For further information, please visit www.aamg.co.

Media Enquiries

WeR1 Consultants Pte Ltd 3 Philip Street #12-01 Royal Group Building Singapore 048693 Tel: (+65) 6737 4844, Fax: (+65) 67374944

Ms Rachael De Foe; rachaeldefoe@wer1.net